28 years of historical data (1998–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BioMarin Pharmaceutical Inc. trades at 34.3x earnings, 79% below its 5-year average of 166.0x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 45%. On a free-cash-flow basis, the stock trades at 16.4x P/FCF, 90% below the 5-year average of 156.0x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $11.9B | $10.4B | $12.9B | $18.5B | $19.6B | $16.2B | $16.8B | $15.1B | $15.1B | $15.6B | $13.8B |
| Enterprise Value | $11.1B | $9.7B | $12.6B | $18.8B | $19.9B | $16.7B | $17.2B | $15.6B | $15.4B | $16.1B | $14.0B |
| P/E Ratio → | 34.29 | 386.86 | 29.74 | 109.57 | 137.99 | — | 19.36 | — | — | — | — |
| P/S Ratio | 3.68 | — | 4.53 | 7.64 | 9.33 | 8.75 | 9.03 | 8.88 | 10.12 | 11.84 | 12.33 |
| P/B Ratio | 2.00 | 1.71 | 2.29 | 3.73 | 4.25 | 3.79 | 4.09 | 4.85 | 5.09 | 5.54 | 4.98 |
| P/FCF | 16.36 | 14.32 | 27.20 | 295.26 | 355.93 | 87.18 | — | — | — | — | — |
| P/OCF | 14.32 | 12.54 | 22.57 | 116.00 | 111.17 | 53.05 | 196.90 | 313.66 | 746.95 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
BioMarin Pharmaceutical Inc.'s enterprise value stands at 18.2x EBITDA, 91% below its 5-year average of 202.6x. The Healthcare sector median is 13.8x, placing the stock at a 31% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 4.43 | 7.78 | 9.51 | 9.02 | 9.27 | 9.13 | 10.35 | 12.28 | 12.58 |
| EV / EBITDA | 18.18 | — | 21.76 | 64.84 | 75.78 | 648.19 | 279.37 | 3212.70 | — | 220.47 | — |
| EV / EBIT | — | — | 22.80 | 92.96 | 121.95 | — | — | — | — | 5191.53 | — |
| EV / FCF | — | 13.33 | 26.58 | 300.70 | 362.64 | 89.89 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
BioMarin Pharmaceutical Inc. earns an operating margin of 16.6%. Operating margins have expanded from 7.7% to 17.0% over the past 3 years, signaling improving operational efficiency. ROE of 5.7% is modest. ROIC of 7.4% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.1% | — | 79.7% | 78.0% | 76.0% | 74.5% | 71.8% | 78.9% | 78.9% | 81.6% | 81.2% |
| Operating Margin | 16.6% | — | 17.0% | 7.7% | 7.7% | -4.5% | -2.3% | -5.9% | -8.3% | -1.1% | -71.9% |
| Net Profit Margin | 10.8% | — | 15.0% | 6.9% | 6.8% | -3.5% | 45.9% | -1.4% | -5.2% | -8.9% | -56.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.7% | 0.5% | 8.0% | 3.5% | 3.2% | -1.5% | 23.6% | -0.8% | -2.7% | -4.2% | -24.4% |
| ROA | 4.6% | 0.4% | 6.2% | 2.5% | 2.3% | -1.1% | 16.2% | -0.5% | -1.7% | -2.7% | -16.3% |
| ROIC | 7.4% | — | 6.8% | 2.7% | 2.5% | -1.3% | -0.8% | -2.2% | -2.8% | -0.3% | -21.1% |
| ROCE | 7.8% | — | 8.0% | 3.2% | 2.9% | -1.5% | -1.0% | -2.6% | -3.2% | -0.4% | -23.4% |
Solvency and debt-coverage ratios — lower is generally safer
BioMarin Pharmaceutical Inc. carries a Debt/EBITDA ratio of 1.0x, which is very conservative (69% below the sector average of 3.1x). The company holds a net cash position — cash of $1.3B exceeds total debt of $597M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 48.9x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.11 | 0.22 | 0.24 | 0.26 | 0.26 | 0.28 | 0.28 | 0.42 | 0.25 |
| Debt / EBITDA | 0.97 | — | 1.12 | 3.78 | 4.16 | 42.40 | 17.61 | 177.33 | — | 16.05 | — |
| Net Debt / Equity | — | -0.12 | -0.05 | 0.07 | 0.08 | 0.12 | 0.11 | 0.13 | 0.11 | 0.21 | 0.10 |
| Net Debt / EBITDA | -1.17 | — | -0.51 | 1.17 | 1.40 | 19.54 | 7.09 | 87.01 | — | 7.88 | — |
| Debt / FCF | — | -0.99 | -0.62 | 5.44 | 6.71 | 2.71 | — | — | — | — | — |
| Interest Coverage | 48.95 | — | 38.23 | 10.72 | 10.08 | -5.37 | -1.48 | -4.28 | -2.83 | -0.34 | -20.34 |
Net cash position: cash ($1.3B) exceeds total debt ($597M)
Short-term solvency ratios and asset-utilisation metrics
BioMarin Pharmaceutical Inc.'s current ratio of 5.21x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.50x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.51x to 5.21x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.21 | 5.21 | 5.33 | 2.51 | 4.67 | 4.16 | 4.76 | 2.08 | 3.93 | 2.70 | 3.24 |
| Quick Ratio | 3.50 | 3.50 | 3.29 | 1.57 | 3.15 | 2.74 | 3.34 | 1.35 | 2.92 | 2.12 | 2.43 |
| Cash Ratio | 2.06 | 2.06 | 1.87 | 0.91 | 2.19 | 1.86 | 2.16 | 0.81 | 2.07 | 1.71 | 1.80 |
| Asset Turnover | — | — | 0.41 | 0.35 | 0.33 | 0.31 | 0.32 | 0.36 | 0.34 | 0.28 | 0.28 |
| Inventory Turnover | 0.57 | — | 0.47 | 0.48 | 0.56 | 0.61 | 0.75 | 0.53 | 0.59 | 0.51 | 0.59 |
| Days Sales Outstanding | — | — | 84.48 | 95.61 | 80.33 | 73.82 | 87.96 | 80.84 | 83.86 | 72.62 | 70.36 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BioMarin Pharmaceutical Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 2.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.9% | 0.3% | 3.4% | 0.9% | 0.7% | — | 5.2% | — | — | — | — |
| FCF Yield | 6.1% | 7.0% | 3.7% | 0.3% | 0.3% | 1.1% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.2% | 0.2% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.2% | 0.2% | 0.0% |
| Shares Outstanding | — | $192M | $197M | $192M | $189M | $183M | $192M | $179M | $177M | $174M | $166M |
Compare BMRN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| BMRNYou | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| CORT | $4B | 43.5 | 78.6 | 26.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 28 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BMRN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonBioMarin Pharmaceutical Inc.'s current P/E ratio is 34.3x. The historical average is 62.3x. This places it at the 50th percentile of its historical range.
BioMarin Pharmaceutical Inc.'s current EV/EBITDA is 18.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 52.2x.
BioMarin Pharmaceutical Inc.'s return on equity (ROE) is 5.7%. The historical average is -17.9%.
Based on historical data, BioMarin Pharmaceutical Inc. is trading at a P/E of 34.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
BioMarin Pharmaceutical Inc. has 77.1% gross margin and 16.6% operating margin. Operating margin between 10-20% is typical for established companies.
BioMarin Pharmaceutical Inc.'s Debt/EBITDA ratio is 1.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.